Материалов:
1 005 012

Репозиториев:
30

Авторов:
761 409

По вашему запросу найдено документов: 8382

Страница 12 из 839

Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE in patients with massive pulmonary embolism and hemodynamic instability. Methods: A randomized, open

Safety and immunogenicity of the gamtbvac, the recombinant subunit tuberculosis vaccine candidate: A phase II, multi-center, double-blind, randomized, placebo-controlled study10, and a dextran-binding domain (DBD). Phase II of a double-blind, randomized, multicenter, placebo

A surgical polypragmasy: Koninckx PR, Corona R, Timmerman D, Verguts J, Adamyan L. Peritoneal full-conditioning reduces postoperative adhesions and pain: A randomised controlled trial in deep endometriosis surgery. J Ovarian Res. 2013 Dec 11;6(1):90-conditioning reduces postoperative adhesions and pain: A randomised controlled trial in deep endometriosis surgery. J

NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-guided therapy in acute decompensated heart failure PRIMA II randomized controlled trial (Can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?) failure PRIMA II randomized controlled trial (Can NT-ProBNP-guided therapy during hospital admission

The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS CardioGroup I): A randomized controlled trialGroup I): A randomized controlled trial

FORTELYZIN® VERSUS METALYSE® IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: RESULTS OF MULTICENTER RANDOMIZED trial FRIDOM 1 TRIAL FRIDOM 1 TRIAL FRIDOM 1 study was performed up to 30 days after randomization. Results: The trial showed that after Fortelyzin

Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial, to March 23, 2019, 336 (87%) were included in the trial. 168 (50%) patients were randomly assigned

Cerebrolysin for acute ischaemic stroke/668 in placebo group; RR 0.97 95% CI 0.86 to 1.09, random-effects model (3 trials, 1335 participants, moderate

Cerebrolysin for acute ischaemic stroke/667 in cerebrolysin group versus 307/668 in placebo group; RR 0.97 95% CI 0.86 to 1.09, random-effects model (3 trials

Cerebrolysin for acute ischaemic stroke: We searched the Cochrane Stroke Trials Register, CENTRAL, MEDLINE, Embase, Web of Science Core

Страница 12 из 839